Skip to main
MDT

Medtronic (MDT) Stock Forecast & Price Target

Medtronic (MDT) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 17%
Buy 44%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Medtronic is acquiring Scientia Vascular for $550M, which complements its existing Neurovascular business and expands its product portfolio in a fragmented market. This acquisition is expected to be minimally dilutive to adjusted EPS in FY27 and accretive thereafter, and demonstrates MDT's strategy of pursuing tuck-in acquisitions for stronger organic growth. With a deep product pipeline driving revenue growth and potential margin improvement, MDT is positioned for high-single digit EPS growth, but inconsistent execution and quarterly results may prevent P/E multiple expansion.

Bears say

Medtronic is currently facing a negative outlook due to unsuccessful new product launches and potential market share loss in certain product categories. This, combined with flat or declining operating margins, may result in below-consensus earnings. Additionally, the company's non-GAAP gross and operating margins have been down year-over-year as unfavorable mix, tariffs, and costs offset favorable currency, pricing, and operating expense leverage. However, there is potential for a strong product cycle in the future, which could lead to improved organic revenue growth and earnings.

Medtronic (MDT) has been analyzed by 18 analysts, with a consensus rating of Buy. 17% of analysts recommend a Strong Buy, 44% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medtronic (MDT) Forecast

Analysts have given Medtronic (MDT) a Buy based on their latest research and market trends.

According to 18 analysts, Medtronic (MDT) has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $108.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $108.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medtronic (MDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.